Potential therapeutic role of budesonide to reduce COVID-19 severity.
作者信息
Mohiuddin Md, Kasahara Kazuo
机构信息
Department of Respiratory Medicine, Kanazawa University, Ishikawa, Japan.
Department of Respiratory Medicine, Kanazawa University, Ishikawa, Japan.
出版信息
J Infect Public Health. 2022 Jan;15(1):109-111. doi: 10.1016/j.jiph.2021.11.003. Epub 2021 Nov 12.
PMID:34802976
Abstract
摘要
相似文献
[1]
Potential therapeutic role of budesonide to reduce COVID-19 severity.
J Infect Public Health. 2022-1
[2]
[4]
[5]
[Inhaled budesonide in the treatment of COVID-19].
Internist (Berl). 2021-8
[6]
Inhaled budesonide for early treatment of COVID-19.
Lancet Respir Med. 2021-7
[7]
High-dose budesonide for early COVID-19.
Lancet. 2021-12-11
[8]
High-dose budesonide for early COVID-19.
Lancet. 2021-12-11
[9]
Inhaled budesonide for early treatment of COVID-19.
Lancet Respir Med. 2021-7
[10]
Inhaled budesonide for early treatment of COVID-19.
Lancet Respir Med. 2021-7
本文引用的文献
[2]
Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19.
Lancet Respir Med. 2021-7
[3]
[4]
[5]
[6]
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon.
J Allergy Clin Immunol. 2021-2
[7]
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.
Int J Antimicrob Agents. 2020-6-10
[8]
The hallmarks of COVID-19 disease.
PLoS Pathog. 2020-5-22
[9]
[10]
Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.
Am J Trop Med Hyg. 2020-6
Zotero 插件